Ophelia, a NYC-based digital provider of medication-assisted treatment (MAT) for opioid use disorder (OUD), raised a $50m Series B funding.
The round was led by Tiger Global with participation from Menlo Ventures, General Catalyst, Refactor Capital, 640 Oxford Ventures, Interplay Ventures, PillPack founder Elliot Cohen, and Good Friends, the fund launched by the founders of Warby Parker, Harry’s, and Allbirds.
The company intends to use the funfd to expand its treatment program to more patients and clinicians across the United States, integrate with additional payors and partners, and develop its clinician recruitment, training, and support platform.
Led by Zack Gray, co-founder and CEO, Ophelia is a digital provider of medication-assisted treatment (MAT) for opioid use disorder (OUD). At its core is the Ophelia Care Model, a team-based clinical model and software platform developed by experts in addiction medicine and psychiatry. Its clinical protocols are comprehensive and informed by the latest standards of care, including synchronous video-based telehealth visits, FDA-approved medications, urine drug screens, on-demand messaging, optional groups, care coordination services, and treatment for commonly co-occurring psychiatric disorders such as depression and anxiety.
Ophelia is licensed to provide care in 27 states and contracted with Medicaid, Medicare, and Commercial insurers covering 75 million American lives.